Achieve Life Sciences, Inc. (ACHV)
Achieve Life Sciences develops cytisinicline, a drug candidate intended to help people quit smoking or vaping. It last closed at $6.78 on Nov 9, up 0.89% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From ACHV's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on ACHV in the past 90 days. The average target is $18.00, with a high of $18.00 and a low of $18.00, compared with the last close of $6.78.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 30 | Stifel | Initiated | Buy | $18 |
| Aug 13 | Morgan Stanley | Initiated | Buy | $13 |
| Jun 22 | HC Wainwright & Co. | Reiterated | Buy | $12 |
| Apr 21 | Canaccord Genuity | Initiated | Buy | $13 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 16% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 48). The nearest support is the Pivot at $6.74, and the nearest resistance the Pivot R1 at $6.95.
| RSI (14) | 47.93 | Middle of its range | Neutral |
| MACD | -0.14 | Above its signal line | Bullish |
| Stochastic | 36.0 | Middle of its range | Neutral |
| ADX (14) | 17.9 | No clear trend | |
| Williams %R | -49.0 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 2.1 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +3.7% | Change over 10 sessions | Bullish |
| ATR (14) | $0.43 | Typical daily range, 6.4% of price |
| RSI (14) | 52.52 | Middle of its range | Neutral |
| MACD | 0.38 | Below its signal line | Bearish |
| Stochastic | 26.1 | Middle of its range | Neutral |
| ADX (14) | 28.8 | Trending up | |
| Williams %R | -76.9 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -33.9 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −20.1% | Change over 10 sessions | Bearish |
| ATR (14) | $0.87 | Typical daily range, 12.9% of price |
What happened before
See how ACHV did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ACHV has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in ACHV in the last 90 days.
ACHV Institutional Ownership
Full report →- ▲76 buying vs 37 selling
- ▲Held by funds +11.4 pts
- ▲Funds holding +20
- ▲Superinvestors: 3 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 132 | 112 | +17.9% |
| In funds' top 10 | 2 | 2 | 0.0% |
| Held by funds | 86.5% | 75.2% | +11.4 pts |
| New / increased | 33 / 43 | 47 / 36 | −8.4% |
| Reduced / sold out | 24 / 13 | 15 / 17 | +15.6% |
| Put/call ratio | 0.00 | 0.00 | −100.0% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACHV is in one of them and how their past ACHV trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ACHV in an article yet. Here's the latest on the wider market.
About Achieve Life Sciences
Achieve Life Sciences is a specialty pharmaceutical company based in Seattle, Washington. It is developing cytisinicline, a drug candidate for treating nicotine dependence in people who want to quit smoking or vaping. The drug has not yet been approved by U.S. regulators. Its target customers are adult smokers and vapers, and the company also holds rights to commercialize the drug in regions outside a European partner's territory.
- Headquarters
- Seattle, WA


